Exact Sciences Corp (NASDAQ: EXAS) is a molecular diagnostics company that develops and commercializes cancer screening and detection tests. Revenue is generated on a transactional basis, collected per test processed, with reimbursement flowing primarily through insurance payors. The company is headquartered in Madison, Wisconsin and filed its most recent annual report (10-K) on February 13, 2026, covering the fiscal year ended December 31, 2025. Its common stock traded at $53.14 per share as of June 28, 2025. The filing confirms Exact Sciences holds well-known seasoned issuer status under SEC Rule 405. Beyond these filing-level details, the excerpts provided do not supply sufficient segment revenue figures, customer concentration data, named competitors, or geographic mix to characterize the business further with source-grounded specificity.

Revenue model

Transactional revenue per diagnostic test processed, with reimbursement collected from insurance payors. Specific revenue figures and segment breakdowns are not supported by the provided filing excerpts.

Products and services

Cancer screening and detection molecular diagnostic tests. Specific product names and revenue contributions are not supported by the provided filing excerpts.

Customers and end markets

End markets include cancer screening for patients, with reimbursement from insurance payors. Specific customer concentration or payor mix data are not supported by the provided filing excerpts.

Value-chain role

Diagnostic test developer and laboratory services provider in the cancer screening value chain.

Geographic exposure

Headquartered in Madison, Wisconsin. Geographic revenue mix is not supported by the provided filing excerpts.

Source: SEC 10-K, filed 2026-02-13

Industry: Services-Medical Laboratories Peers: Apellis Pharmaceuticals Inc Cytokinetics Inc Exelixis Inc Global Blood Therapeutics, Inc. Halozyme Therapeutics Inc Ionis Pharmaceuticals Inc Legend Biotech Corp